Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind Study
- 1 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 9 (1) , 271-281
Abstract
Erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH‐LUTS) commonly coexist in aging men. Tadalafil, a phosphodiesterase type 5 inhibitor approved for treating ED, is currently being evaluated for treating BPH‐LUTS. This multinational Phase 3 study assessed effects of tadalafil 2.5 or 5 mg once daily on ED and BPH‐LUTS in men with both conditions during 12 weeks of double‐blinded therapy. Men were ≥45 years old, sexually active, and experiencing ED for ≥3 months and BPH‐LUTS for >6 months. Randomization (baseline) followed a 4‐week placebo lead‐in; changes from baseline were assessed via analysis of covariance and compared to placebo. A gatekeeping procedure controlled for multiple comparisons of co‐primary and key secondary measures at end point (last post‐baseline observation). The co‐primary measures were the International Index of Erectile Function‐erectile function (IIEF‐EF) domain and International Prostate Symptom Score (IPSS) score; key secondary measures were the Sexual Encounter Profile Question 3 (SEP Q3) and BPH Impact Index (BII). Treatment‐emergent adverse events, serious adverse events, orthostatic vital signs, clinical laboratory and uroflowmetry parameters, and postvoid residual volume were assessed. Tadalafil 2.5 mg (N = 198) and 5 mg (N = 208) significantly improved IIEF‐EF domain scores (both P < 0.001) vs. placebo (N = 200) at end point. For IPSS, improvements were significant with tadalafil 5 mg (P < 0.001), but not 2.5 mg, for observations from 2 weeks through end point (least‐squares mean ± standard error change from baseline at end point, placebo −3.8 ± 0.5, tadalafil 2.5 mg −4.6 ± 0.4, and 5 mg −6.1 ± 0.4). Tadalafil 5 mg significantly improved SEP Q3 and BII (P < 0.001). Overall, tadalafil was well tolerated with no clinically adverse changes in orthostatic vital signs or uroflowmetry parameters. Tadalafil 5 mg significantly improved both ED and BPH‐related outcomes through 12 weeks and was well tolerated. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, and Secrest RJ. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo‐controlled, double‐blind study. J Sex Med 2012;9:271–281.Keywords
This publication has 20 references indexed in Scilit:
- Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of actionNeurourology and Urodynamics, 2011
- Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1‐year, open‐label extension studyBJU International, 2011
- A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasiaBJU International, 2010
- Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatmentBJU International, 2010
- A Dunnett–Bonferroni‐based parallel gatekeeping procedure for dose–response clinical trials with multiple endpointsPharmaceutical Statistics, 2008
- Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2007
- Sildenafil Citrate Improves Erectile Function and Urinary Symptoms in Men With Erectile Dysfunction and Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized, Double-Blind TrialJournal of Urology, 2007
- Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2006
- Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the USInternational Journal Of Impotence Research, 2006
- Effects of ??1-Adrenoceptor Antagonists on Male Sexual FunctionDrugs, 2006